Business
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 statusLate-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026Ziihera engineered and initially developed by Zymeworks using our proprietary Azymetric™ technology plat
About this update from Zymeworks Inc.
[{"type":"image","alt":"Zymeworks Inc.","displaySize":"","headline":null,"caption":"Zymeworks Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Mr3NL5l3JfRng99mnVVlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 status","length":278,"tagName":"p"}]},{"val":[{"type":"text","content":"Late-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Ziihera engineered and initially developed by Zymeworks using our proprietary Azymetric™ technology platform","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Zymeworks is eligible to receive up to $440.0 million in milestone payments to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China","length":185,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":694,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.","length":680,"tagName":"p"},{"type":"text","content":"The data will be presented as a late-breaking oral presentation at ...